Amendment to

BULLETIN #78

Manitoba Drug Benefits and Interchangeability Formulary Amendments

The following amendment will take effect on July 17, 2014.



The Manitoba Drug Interchangeability Formulary Regulation will be avaliable on the Manitoba Health website http://www.gov.mb.ca/health/mdbif/ on the effective date of July 17, 2014

Bulletin 78 is currently available for download: http://www.gov.mb.ca/health/mdbif/bulletin78.pdf

Apotex Inc. has confirmed they cannot supply Apo-Temozolomide as communicated in Bulletin 78.

Effective July 17, 2014 the following product will NOT be added as a Part 1 benefit and will NOT be made interchangeable:

02413035 02413043	5 mg	5.8500
02413094 02413116 02413124	20 mg 100 mg Capsule 140 mg 180 mg	17.9550 89.9770 125.9680 253.6726

Note: Temodal (temozolomide) 5 and 180 mg capsules will continue to be reimbursed as single source products.